Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Three months ended July 31, 2015 (the first quarter of fiscal 2016). Financial statements are unaudited; amounts below are in thousands of dollars unless noted.
Business context
Champions develops and sells oncology research and personalized-treatment solutions using its TumorGraft platform. Personalized Oncology Solutions (POS) serves physicians and patients; Translational Oncology Solutions (TOS) serves pharmaceutical and biotechnology companies. TOS generated 82.8% of quarterly revenue.
Financial results and liquidity
| Metric | Q1 ended July 31, 2015 | Prior-year quarter |
|---|---|---|
| Revenue | $2,822 | $1,912 |
| Operating loss | $(2,897) | $(3,729) |
| Net loss | $(2,913) | $(3,548) |
| Net loss per share, basic and diluted | $(0.33) | $(0.64) |
| Cash used in operations | $(2,543) | $(2,788) |
- Revenue mix: POS $485, up 42.2%; TOS $2,337, up 48.8%. TOS growth was attributed to prior-quarter bookings, expanded sales capacity, and platform growth.
- POS gross margin was negative 36.3%, improved from negative 122%, attributed to higher-margin non-core revenue and lower core costs. TOS gross margin declined to 31% from 38.6% as TOS costs rose 67%, faster than revenue.
- Research and development expense fell 22.7% to $1,100, primarily because of lower one-time TumorBank genomic-characterization costs. General and administrative expense declined 9.9% to $1,317; sales and marketing expense was approximately unchanged at $1,029.
- Stock-based compensation was $775, a significant noncash expense. The filing reports no recurring assets or liabilities measured at fair value.
- Cash and cash equivalents were $6,760 at July 31, down from $9,357 at April 30; working capital was $4,800. Total liabilities were $3,945 and stockholders’ equity was $5,903. The filing reports no off-balance-sheet debt; capital-lease minimum payments totaled $109 through 2020.
- Cash used in investing was $29, mainly for equipment; cash used in financing was $25, including private-placement issuance costs and capital-lease payments. No conventional borrowing balance is identified in the supplied filing text.
Changes, outlook, and risks
- Compared with the prior-year quarter, revenue grew substantially and operating loss narrowed, but the company remained loss-making. Net loss improved partly alongside a prior-year $155 gain related to warrant fair value; the warrants were reclassified into equity, so there was no comparable gain in 2015.
- Management stated that available cash was expected to fund operations through at least May 31, 2016. The company expected continued operating losses and said additional external capital may be needed to continue beyond that point. Financing may be unavailable or dilutive; without it, research and development or other activities could be reduced, delayed, or eliminated.
- The company recognized $24 of revenue under its Teva agreement in the quarter, versus $322 in the prior-year quarter. Future milestone and royalty payments are conditional.
- Potential registration-rights penalties related to the March 2015 private placement were not accrued because management did not consider payment probable. The company reported $100 of unrecognized tax benefits and no accrued interest or penalties. It reported no legal proceedings.
- Subsequent event: the company’s common stock began trading on the Nasdaq Capital Market on August 21, 2015. A one-for-twelve reverse split became effective August 12; share and per-share data were retrospectively adjusted.
- Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Reconcile reported revenue growth: the statements show $2,822 versus $1,912, a difference of $910 and approximately 47.6%; MD&A instead states an increase of $892 and 46.7%.
- Track cash burn and financing needs against management’s stated runway through May 31, 2016, including any subsequent financing or changes in expected spending.
- Assess whether TOS growth can sustain margins and whether POS can improve from its negative gross margin.
- Review dilution exposure: 2,109,840 warrants and 2,014,507 options were outstanding at July 31, 2015; the filing’s share and per-share figures reflect the reverse split.
- Monitor Teva-related revenue and any registration-rights penalties or other contingencies that may arise.